Cargando…
Aberrant Signaling Pathways in Glioma
Glioblastoma multiforme (GBM), a WHO grade IV malignant glioma, is the most common and lethal primary brain tumor in adults; few treatments are available. Median survival rates range from 12–15 months. The biological characteristics of this tumor are exemplified by prominent proliferation, active in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759196/ https://www.ncbi.nlm.nih.gov/pubmed/24212955 http://dx.doi.org/10.3390/cancers3033242 |
_version_ | 1782477221874630656 |
---|---|
author | Nakada, Mitsutoshi Kita, Daisuke Watanabe, Takuya Hayashi, Yutaka Teng, Lei Pyko, Ilya V. Hamada, Jun-Ichiro |
author_facet | Nakada, Mitsutoshi Kita, Daisuke Watanabe, Takuya Hayashi, Yutaka Teng, Lei Pyko, Ilya V. Hamada, Jun-Ichiro |
author_sort | Nakada, Mitsutoshi |
collection | PubMed |
description | Glioblastoma multiforme (GBM), a WHO grade IV malignant glioma, is the most common and lethal primary brain tumor in adults; few treatments are available. Median survival rates range from 12–15 months. The biological characteristics of this tumor are exemplified by prominent proliferation, active invasiveness, and rich angiogenesis. This is mainly due to highly deregulated signaling pathways in the tumor. Studies of these signaling pathways have greatly increased our understanding of the biology and clinical behavior of GBM. An integrated view of signal transduction will provide a more useful approach in designing novel therapies for this devastating disease. In this review, we summarize the current understanding of GBM signaling pathways with a focus on potential molecular targets for anti-signaling molecular therapies. |
format | Online Article Text |
id | pubmed-3759196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37591962013-09-04 Aberrant Signaling Pathways in Glioma Nakada, Mitsutoshi Kita, Daisuke Watanabe, Takuya Hayashi, Yutaka Teng, Lei Pyko, Ilya V. Hamada, Jun-Ichiro Cancers (Basel) Review Glioblastoma multiforme (GBM), a WHO grade IV malignant glioma, is the most common and lethal primary brain tumor in adults; few treatments are available. Median survival rates range from 12–15 months. The biological characteristics of this tumor are exemplified by prominent proliferation, active invasiveness, and rich angiogenesis. This is mainly due to highly deregulated signaling pathways in the tumor. Studies of these signaling pathways have greatly increased our understanding of the biology and clinical behavior of GBM. An integrated view of signal transduction will provide a more useful approach in designing novel therapies for this devastating disease. In this review, we summarize the current understanding of GBM signaling pathways with a focus on potential molecular targets for anti-signaling molecular therapies. Molecular Diversity Preservation International (MDPI) 2011-08-10 /pmc/articles/PMC3759196/ /pubmed/24212955 http://dx.doi.org/10.3390/cancers3033242 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Nakada, Mitsutoshi Kita, Daisuke Watanabe, Takuya Hayashi, Yutaka Teng, Lei Pyko, Ilya V. Hamada, Jun-Ichiro Aberrant Signaling Pathways in Glioma |
title | Aberrant Signaling Pathways in Glioma |
title_full | Aberrant Signaling Pathways in Glioma |
title_fullStr | Aberrant Signaling Pathways in Glioma |
title_full_unstemmed | Aberrant Signaling Pathways in Glioma |
title_short | Aberrant Signaling Pathways in Glioma |
title_sort | aberrant signaling pathways in glioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759196/ https://www.ncbi.nlm.nih.gov/pubmed/24212955 http://dx.doi.org/10.3390/cancers3033242 |
work_keys_str_mv | AT nakadamitsutoshi aberrantsignalingpathwaysinglioma AT kitadaisuke aberrantsignalingpathwaysinglioma AT watanabetakuya aberrantsignalingpathwaysinglioma AT hayashiyutaka aberrantsignalingpathwaysinglioma AT tenglei aberrantsignalingpathwaysinglioma AT pykoilyav aberrantsignalingpathwaysinglioma AT hamadajunichiro aberrantsignalingpathwaysinglioma |